Cart
sales@molnova.com
diaminohydroxypropanetetraacetic acid
CAS No. 3148-72-9
diaminohydroxypropanetetraacetic acid( —— )
Catalog No. M22415 CAS No. 3148-72-9
Diaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 45 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 104 | In Stock |
|
| 25MG | 177 | In Stock |
|
| 50MG | 266 | In Stock |
|
| 100MG | 399 | In Stock |
|
| 200MG | 588 | In Stock |
|
| 500MG | 888 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namediaminohydroxypropanetetraacetic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionDiaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others
-
DescriptionDiaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3148-72-9
-
Formula Weight322.27
-
Molecular FormulaC11H18N2O9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
STM3006
STM3006 is an orally active, selective and and potent METTL3 inhibitor with antitumor activity for the study of acute myeloid leukemia (AML).
-
PPIase-Parvulin Inhi...
PPIase-Parvulin Inhibitor is a cell-pemeable inhibitor of the Pin1 and Pin4.
-
TAT 14
TAT 14, a 14-mer peptide, is an Nrf2 activator with anti-inflammatory properties. TAT-14 increases Nrf2 protein levels due to targeting the Nrf2 binding site on Keap1, but has no effect on Nrf2 mRNA expression.
